Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01611610
Other study ID # SMA Europe
Secondary ID
Status Completed
Phase N/A
First received May 30, 2012
Last updated March 4, 2014
Start date May 2011
Est. completion date May 2013

Study information

Verified date March 2014
Source Institut de Myologie, France
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

The aim of this project is to establish a network of clinical teams including the major neuromuscular centers in Europe.

We plan to work together to find the best common outcome measures for the following multicenter therapeutic trials.


Description:

16 patients (6 ambulant and 10 non ambulant), affected by type II and type III SMA will be enrolled and assessed at baseline and 6 and 12 months later. Non ambulant patients will be assessed using the modified version of the Hammersmith Motor Functional Scale while ambulant patients will be assessed using the extended module of the Hammersmith Motor Functional Scale and timed items, the 6 minute walk and a step activity monitor. All patients will also be assessed using the Motor Function Measure (MFM), that covers the whole range of activities for both ambulant and non ambulant patients. All measures will undergo a process of validation including inter observer reliability. This information will be most valuable for any future trial and will make the groups involved ready to participate to future collaborative studies saving a lot of time on the preliminary aspects (validation, reliability, training) that will be fulfilled by the present study. The study will also provide natural history data for a 12 month period on patients with SMA II and III.


Recruitment information / eligibility

Status Completed
Enrollment 4
Est. completion date May 2013
Est. primary completion date May 2013
Accepts healthy volunteers No
Gender Both
Age group 30 Months to 18 Years
Eligibility Inclusion Criteria for ambulant patients:

- age between 30 months and 24 years

- documented SMA diagnosis by genetic tests; Each should also have the determination of the SMN2 copy number

- able to walk 10 meters without support

- subject who signed an informed consent- subject affiliated to a social security system

Inclusion Criteria non ambulant patients:

- documented diagnosis of SMA by genetic tests

- not able to walk 10 meters without support

- subject affiliated to a social security system

- subject who signed an informed consent

Exclusion Criteria:

- Patient who are currently involved in other clinical trials

- severe intellectual impairment limiting the comprehension of the demanded tasks

- acute neurologic, inflammatory, infectious, endocrine, orthopedic disease in the month preceding the inclusion

- chronic neurologic (besides SMA), inflammatory, infectious, endocrine, orthopedic disease which are not a natural consequence of SMA

- spinal surgery scheduled 6 months before or within 12 months after enrollment

- pregnant women

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label


Intervention

Other:
Functional tests
The ambulant patients will perform MFM (20 items) Hammersmith modified module - MHMFS Timed tests (time to rise from the floor,...) 6 minute walk test PedsQL - neuromuscular module
Functional tests
The non-ambulant patients will perform: MFM (20 items) Hammersmith modified module - MHMFS Upper Limb Functional Items Egen Klassifikation 2 questionnaire - EK2 PedsQL questionnaire - neuromuscular module

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Institut de Myologie, France

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in total score of Motor Function Measure at one year at baseline and one year after No
Secondary Change from baseline of Pediatric Quality of Life Inventory Score at one year Pediatric Quality of Life Inventory - neuromuscular module at baseline and one year after No
See also
  Status Clinical Trial Phase
Completed NCT04851873 - Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) Phase 3
Completed NCT03223051 - Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy N/A
Completed NCT04335942 - Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor N/A
Recruiting NCT05794139 - Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy Phase 2
Not yet recruiting NCT06300996 - Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb N/A
Completed NCT02003937 - Aerobic Training in Patients With Spinal Muscular Atrophy Type III N/A
Not yet recruiting NCT00961103 - Motor Development and Orthoses in Spinal Muscular Atrophy (SMA) N/A
Completed NCT00227266 - Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy Phase 2
Completed NCT00374075 - Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy Phase 1
Enrolling by invitation NCT05539456 - Reliability and Validity of the Turkish Version of the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old
Recruiting NCT05779956 - Personalized Medicine for SMA: a Translational Project
Recruiting NCT03300869 - Natural History of Types 2 and 3 SMA in Taiwan
Recruiting NCT03217578 - Neonatal Spinal Muscular Atrophy (SMA) Screening
Completed NCT01703988 - An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Phase 1/Phase 2
Withdrawn NCT02235090 - Study of Feasibility to Reliably Measure Functional Abilities' Changes in Nonambulant Neuromuscular Patients Without Trial Site Visiting N/A
Completed NCT02123186 - Newborn Screening for Spinal Muscular Atrophy N/A
Completed NCT00756821 - A Pilot Study of Biomarkers for Spinal Muscular Atrophy N/A
Completed NCT00004771 - Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease Phase 2
Recruiting NCT05366465 - Quality of Life and Participation of the Adult With Spinal Muscular Atrophy in France
Recruiting NCT06310421 - Spinal Muscular Atrophy Neonatal Screening Program